Literature DB >> 10945856

Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation.

N Harada1, K Okajima, K Murakami, S Usune, C Sato, K Ohshima, T Katsuragi.   

Abstract

To examine whether adenosine reduces ischemia/reperfusion (I/R)-induced liver injury by inhibiting leukocyte activation via A(2) receptor (A(2)R) stimulation, we investigated the effects of adenosine and selective A(2A) receptor (A(2A)R) agonists (YT-146 and CGS21680C) on I/R-induced liver injury in rats. Adenosine, YT-146, and CGS21680C, in the concentration of 10(-7) to 10(-5) M, significantly inhibited neutrophil elastase release by about 30 to 40% and increased intracellular Ca(2+) concentrations in isolated neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) in vitro. Adenosine, YT-146, and CGS21680C, in the concentration of 10(-7) to 10(-5) M, significantly inhibited tumor necrosis factor (TNF)-alpha production by monocytes stimulated with endotoxin by about 50%. Although ZM241385, a selective A(2A)R antagonist, significantly enhanced the increase in neutrophil elastase release and intracellular Ca(2+) concentrations in neutrophils stimulated with fMLP, this agent did not affect the endotoxin-induced TNF-alpha production by monocytes. Rats were subjected to liver ischemia for 60 min. Serum levels of transaminases increased after hepatic I/R, peaking at 12 h after reperfusion. The i.v. infusion of adenosine (1 and 10 mg/kg/h), YT-146 (0.1 and 1 mg/kg/h), and CGS21680C (0.1 and 1 mg/kg/h) significantly inhibited the I/R-induced increase in serum transaminase levels 12 h after reperfusion. The I/R-induced decrease in hepatic tissue blood flow was significantly prevented by adenosine and YT-146. Hepatic levels of TNF-alpha, cytokine-induced neutrophil chemoattractant (equivalent to human interleukin-8), and myeloperoxidase were significantly increased after I/R. These increases were significantly inhibited by the administration of adenosine, YT-146, and CGS21680C. Although the histological neutrophil accumulation in the liver was significantly increased after I/R as evaluated by the naphthol AS-D chloroacetate technique, the administration of adenosine, YT-146, and CGS21680C significantly inhibited this increase. These findings suggest that adenosine reduces I/R-induced liver injury both by inhibiting the synthesis of inflammatory mediators and by inhibiting neutrophil degranulation directly, probably through A(2A)R stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945856

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

Review 1.  Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control.

Authors:  G Tintinger; H C Steel; R Anderson
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

2.  Therapeutic benefit of pentostatin in severe IL-10-/- colitis.

Authors:  Jeffrey B Brown; Goo Lee; Gery R Grimm; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

3.  Extracellular adenosine controls NKT-cell-dependent hepatitis induction.

Authors:  Meenakshi Subramanian; Radhika Kini; Manasa Madasu; Akiko Ohta; Michael Nowak; Mark Exley; Michail Sitkovsky; Akio Ohta
Journal:  Eur J Immunol       Date:  2014-02-19       Impact factor: 5.532

4.  Inhibition of superoxide anion and elastase release in human neutrophils by 3'-isopropoxychalcone via a cAMP-dependent pathway.

Authors:  Tsong-Long Hwang; Shang-Hsin Yeh; Yann-Lii Leu; Ching-Yuh Chern; Hui-Chi Hsu
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

5.  Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation.

Authors:  Xiaoyang Hua; Kelly D Chason; Corey Jania; Tatiana Acosta; Catherine Ledent; Stephen L Tilley
Journal:  J Pharmacol Exp Ther       Date:  2012-11-13       Impact factor: 4.030

6.  Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.

Authors:  Ali El-Tayeb; Sebastian Michael; Aliaa Abdelrahman; Andrea Behrenswerth; Sabrina Gollos; Karen Nieber; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

7.  Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury.

Authors:  Ashish K Sharma; Victor E Laubach; Susan I Ramos; Yunge Zhao; George Stukenborg; Joel Linden; Irving L Kron; Zequan Yang
Journal:  J Thorac Cardiovasc Surg       Date:  2009-11-11       Impact factor: 5.209

8.  In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor.

Authors:  Alexander Choukèr; Akio Ohta; André Martignoni; Dmitriy Lukashev; Lefteris C Zacharia; Edwin K Jackson; Jürgen Schnermann; Jerrold M Ward; Ines Kaufmann; Brenda Klaunberg; Michail V Sitkovsky; Manfred Thiel
Journal:  Transplantation       Date:  2012-11-15       Impact factor: 4.939

9.  Attenuation of gastric mucosal inflammation induced by aspirin through activation of A2A adenosine receptor in rats.

Authors:  Masaru Odashima; Michiro Otaka; Mario Jin; Koga Komatsu; Isao Wada; Youhei Horikawa; Tamotsu Matsuhashi; Natsumi Hatakeyama; Jinko Oyake; Reina Ohba; Sumio Watanabe; Joel Linden
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

10.  The inhibition of neutrophil elastase ameliorates mouse liver damage due to ischemia and reperfusion.

Authors:  Yoichiro Uchida; Maria Cecilia S Freitas; Danyun Zhao; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.